Overview

Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake

Status:
Completed
Trial end date:
2017-09-08
Target enrollment:
Participant gender:
Summary
27 Type 2 diabetic subjects (HbA1c 7.5 - 9.5%) currently treated with diet and exercise alone or with oral antidiabetic agents will be randomly assigned to one of three treatment groups: insulin detemir, liraglutide, or liraglutide plus detemir (9 subjects per group), on a background of metformin 2000 mg per day. After 3 months' treatment, PET measurements of myocardial fuel selection will take place, under fasting conditions in the morning following that day's treatment injection(s).
Phase:
N/A
Details
Lead Sponsor:
Indiana University
Collaborator:
Novo Nordisk A/S
Treatments:
Insulin
Insulin Detemir
Insulin, Globin Zinc
Liraglutide